A double-blind randomized placebo-controlled study to assess the

Recruiting

99 years and younger

All

1 Location

Brief description of study

This Phase 3, double-blind, randomized, placebo-controlled, parallel-group, multi-center, international study will assess the efficacy, safety and tolerability of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis (IPA).

Eligibility of study

You may be eligible for this study if you meet the following criteria:

Conditions: Medical Research
Age: - 99 Years
Gender: All

Updated on 13 Sep 2024. Study ID: 850845

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

A double-blind randomized placebo-controlled study to assess the safety and efficacy of nebulized PC945 when added to systemic antifungal therapy for the treatment of refractory invasive pulmonary aspergillosis

Brief description of study

Eligibility of study

Find a site

What happens next?

Interested in the study